While Lilly and Novo struggled early on to make enough of their medicines to meet demand, Pfizer already possesses much of the infrastructure needed to manufacture obesity drugs at a global scale, Boshoff said, including eight sterile injectable facilities around the world. The company also has moved production of Metsera’s drugs in-house, from a contract manufacturer, Boshoff said. “We are internalizing everything, because we can,” he said.